Corrigendum to “A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report” (Eur J of Canc (2017) (206–225)(S0959804917309218)(10.1016/j.ejca.2017.04.019))

The authors regret that the original article did not include an acknowledgement of the Dutch Childhood Oncology Group as part of the International Study Committee. The authors would like to add the following acknowledgement: Netherlands – DCOG: Netteke Schouten The authors would like to apologise for any inconvenience caused.